Rabasseda Xavier
Medical Information Department, Prous Science, Barcelona, Spain.
Drugs Today (Barc). 2004 Sep;40(9):773-90. doi: 10.1358/dot.2004.40.9.850497.
Double-blind, placebo-controlled clinical trials have evaluated and demonstrated the efficacy of duloxetine as an antidepressant in patients with major depressive disorders. The drug has been noted to be well tolerated and effective in the control of depressive symptoms. In addition, duloxetine has been shown to be better than placebo and as effective as paroxetine as an antidepressant and also better than placebo for reducing pain in both experimental models and patients. Duloxetine is a safe and well-tolerated new treatment option for depression including anxiety and painful physical symptoms. Furthermore, duloxetine has proven robust efficacy in stress urinary incontinence.
双盲、安慰剂对照临床试验已评估并证明度洛西汀作为抗抑郁药对重度抑郁症患者的疗效。该药物耐受性良好,对控制抑郁症状有效。此外,度洛西汀已被证明在抗抑郁方面优于安慰剂且与帕罗西汀效果相当,在实验模型和患者中减轻疼痛方面也优于安慰剂。度洛西汀是一种安全且耐受性良好的新型抑郁症治疗选择,包括焦虑和疼痛性躯体症状。此外,度洛西汀已在压力性尿失禁方面证明有强大疗效。